An update from Genor Biopharma Holdings Limited ( (HK:6998) ) is now available.
Genor Biopharma Holdings Limited announced a very substantial acquisition involving a proposed merger with a target company, which includes issuing consideration shares under a specific mandate. The announcement also covers a reverse takeover, a new listing application, a whitewash waiver application, and other corporate changes such as a proposed company name change and an increase in authorized share capital. The company has extended deadlines for the new listing application and merger closing, and is preparing the necessary documentation for shareholders. The merger’s completion is contingent on several conditions, including approvals from the Stock Exchange and shareholders, with updates to be provided as developments occur.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on developing and commercializing innovative biologics for the treatment of various diseases.
YTD Price Performance: 16.84%
Average Trading Volume: 1,654
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €124.8M
For an in-depth examination of 6998 stock, go to TipRanks’ Stock Analysis page.